+612 9045 4394
 
CHECKOUT
Drugs for HER-2-positive Breast Cancer : Milestones in Drug Therapy - Maria Sibilia

Drugs for HER-2-positive Breast Cancer

Milestones in Drug Therapy

By: Maria Sibilia (Editor), Christoph C. Zielinski (Editor), Rupert Bartsch (Editor), Thomas W. Grunt (Editor)

Hardcover Published: 10th January 2011
ISBN: 9783034600934
Number Of Pages: 110

Share This Book:

Hardcover

RRP $514.99
$356.25
31%
OFF
or 4 easy payments of $89.06 with Learn more
Ships in 10 to 15 business days

Other Available Editions (Hide)

  • Paperback View Product Published: 25th February 2013
    Ships in 10 to 15 business days
    $310.75

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

From the reviews:

"This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. ... It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. ... Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing." (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)

The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapyp. 1
Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancerp. 33
Trastuzumab Resistance in Breast Cancerp. 51
Treatment with Trastuzumab Beyond Progressionp. 61
Pertuzumab - a HER-2 Dimerisation Inhibitor - for the Treatment of Breast and Other Cancersp. 73
Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancerp. 91
Indexp. 109
Table of Contents provided by Ingram. All Rights Reserved.

ISBN: 9783034600934
ISBN-10: 3034600933
Series: Milestones in Drug Therapy
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 110
Published: 10th January 2011
Publisher: SPRINGER VERLAG GMBH
Country of Publication: CH
Dimensions (cm): 23.37 x 16.0  x 1.52
Weight (kg): 0.3